BENZNIDAZOLE - Generic Drug Details

What are the generic drug sources for benznidazole and what is the scope of freedom to operate?

Benznidazole is the generic ingredient in one branded drug marketed by Chemo Research Sl and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for BENZNIDAZOLE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	24
Patent Applications:	2,884
What excipients (inactive ingredients) are in BENZNIDAZOLE?	BENZNIDAZOLE excipients list
DailyMed Link:	BENZNIDAZOLE at DailyMed

Recent Clinical Trials for BENZNIDAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	PHASE2
Andrea Silvestre de Sousa	PHASE3
Evandro Chagas Institute of Clinical Research	PHASE3

See all BENZNIDAZOLE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for BENZNIDAZOLE

P01CA	Nitroimidazole derivatives
P01C	AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
P01	ANTIPROTOZOALS
P	Antiparasitic products, insecticides and repellents

US Patents and Regulatory Information for BENZNIDAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemo Research Sl	BENZNIDAZOLE	benznidazole	TABLET;ORAL	209570-002	Aug 29, 2017		RX	Yes	Yes
Chemo Research Sl	BENZNIDAZOLE	benznidazole	TABLET;ORAL	209570-001	Aug 29, 2017		RX	Yes	No

Benznidazole Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 8, 2026

Benznidazole is a low-cost, off-patent antiparasitic used to treat Chagas disease caused by Trypanosoma cruzi. Its commercial value is constrained by limited diagnosis, fragmented access, pediatric concentration, and procurement-driven pricing rather than by active patent protection. The U.S. product received FDA approval in 2017 for pediatric patients ages 2 through 12, but the addressable market remains small relative to conventional pharmaceutical products.[1]

The product has strategic value because it is one of the two principal treatments for Chagas disease. Its financial trajectory depends more on public-health programs, Latin American procurement, U.S. orphan-drug economics, and geographic expansion than on premium pricing or patent exclusivity.

What is benznidazole and how is it used?

Benznidazole is a nitroimidazole antiparasitic that eliminates or suppresses T. cruzi, the parasite responsible for Chagas disease. The drug is used primarily during the acute phase of infection, in congenital infection, and in children and younger adults who may obtain greater benefit before irreversible cardiac or gastrointestinal disease develops.

Attribute	Benznidazole
Active ingredient	Benznidazole
Therapeutic area	Chagas disease
Disease pathogen	Trypanosoma cruzi
Drug class	Nitroimidazole antiparasitic
U.S. dosage forms	12.5 mg and 100 mg tablets
FDA approval	August 29, 2017
U.S. labeled population	Pediatric patients ages 2 to 12
U.S. marketer	Exeltis USA
Principal manufacturing origin	Latin America and Spain-linked supply chain
Main competitor	Nifurtimox
Biosimilar exposure	None; benznidazole is a small molecule
Primary commercial channels	Government procurement, specialty distribution, hospitals, and public-health programs

The usual treatment course lasts approximately 60 days. Dosing is weight-based, which makes the 12.5 mg pediatric tablet commercially important. The 100 mg tablet is used when appropriate for larger children and adults, although U.S. labeling historically focused on children ages 2 to 12.[1]

When does benznidazole lose exclusivity?

Benznidazole’s original compound patent protection expired decades ago. The active ingredient is not a new chemical entity in the commercial sense and has been manufactured for many years in Argentina, Brazil, Spain, and other jurisdictions.

The U.S. regulatory exclusivity associated with the 2017 approval was temporary. FDA granted six months of pediatric exclusivity, extending applicable exclusivity linked to the product’s regulatory protection beyond the ordinary period.[1] That period has expired.

U.S. exclusivity timeline

Event	Date or status
FDA approval of benznidazole tablets	August 29, 2017
U.S. pediatric indication	Ages 2 to 12
Pediatric exclusivity	Six months associated with the approval
Current status of original approval exclusivity	Expired
Compound patent position	Historical patents expired
Current U.S. regulatory barrier	Approval, manufacturing, supply, and market-access requirements rather than core patent protection

The product’s lack of meaningful current compound exclusivity does not eliminate commercial barriers. A new entrant would still need to establish pharmaceutical equivalence, bioequivalence where required, manufacturing compliance, adequate supply, and a viable distribution strategy.

What is the FDA regulatory status of benznidazole?

FDA approved benznidazole under New Drug Application 209570. The approval was significant because it created the first FDA-approved treatment specifically for Chagas disease in children ages 2 to 12.[1]

The product was developed through a regulatory pathway applicable to an established drug addressing an orphan disease. Chagas disease is rare in the United States but has a larger population burden in Latin America and among immigrant communities in the U.S.

FDA labeling identifies adverse events including abdominal pain, rash, decreased weight, headache, nausea, vomiting, neutropenia, and peripheral neuropathy. Treatment duration and tolerability can affect adherence, especially in pediatric patients.[1]

What is the Orange Book status of benznidazole?

The FDA Orange Book is the key source for determining listed patents, exclusivity, therapeutic-equivalence information, and approved products.[2] Benznidazole’s commercial position is generally understood to be driven by an approved branded product and limited competition rather than by a durable Orange Book patent estate.

No active composition-of-matter patent should be expected to block generic entry. Any current Orange Book protection would need to arise from a listed formulation, method-of-use, or other product-specific patent rather than from the historical benznidazole molecule.

For commercial planning, the relevant risk is therefore an ANDA or other generic pathway, not a delayed entry caused by a long-lived compound patent.

How many patents cover benznidazole?

Benznidazole has a weak modern patent position compared with newer specialty drugs. Historical patents relating to the compound and its original development are expired or commercially ineffective.

Potentially relevant patent categories include:

1. Tablet formulations and dosage forms.
2. Pediatric dispersible or age-appropriate formulations.
3. Manufacturing and crystallization processes.
4. Combination treatments.
5. Methods of treating specific Chagas disease populations.

These categories may create narrow barriers if valid and enforceable, but they do not recreate broad molecule-level exclusivity. A formulation patent would need to cover a commercially important difference that a generic competitor cannot readily design around.

How strong is the benznidazole patent estate?

The patent estate is weak on the core active ingredient and moderate at most for differentiated formulations or manufacturing processes. Its strength is limited by five factors:

• The compound has been used commercially for decades.
• Multiple manufacturers have production experience.
• The disease market is geographically fragmented.
• Treatment is usually finite rather than chronic.
• Procurement agencies emphasize access and price.

Patent strength is therefore less important than regulatory execution, product quality, supply reliability, and relationships with public-health purchasers.

Are there Paragraph IV challenges to benznidazole?

No major publicly documented Paragraph IV litigation has established a significant U.S. generic challenge to benznidazole. The absence of prominent litigation is consistent with the product’s small market, expired compound protection, and limited expected return on litigation spending.

A generic applicant could still pursue an ANDA and make Paragraph IV certifications against any listed patents. The economic case would depend on whether the applicant could obtain sufficient volume from U.S. pediatric demand, public-health institutions, and off-label adult use.

The likely generic-entry pathway is therefore commercial rather than litigation-led. A competitor may avoid a patent dispute if no meaningful listed patent blocks approval or if the expected market is too small to justify a challenge.

What patent litigation affects benznidazole?

Publicly visible benznidazole litigation has not produced a major market-disrupting judgment or settlement comparable with disputes involving high-revenue oncology, immunology, or cardiovascular products.

No major U.S. settlement agreement is widely associated with a delayed generic launch. The principal legal issues are more likely to involve:

• Product liability and adverse-event claims.
• Distribution agreements.
• Regulatory compliance.
• Procurement contracts.
• Trademark and brand ownership.
• Manufacturing and quality disputes.

Litigation risk is materially lower than for a patented blockbuster. Commercial parties are more likely to negotiate supply and distribution rights than multi-year patent settlements.

What formulations are protected by benznidazole patents?

The commercially relevant formulation distinction is between the 12.5 mg pediatric tablet and the 100 mg tablet. The pediatric dose strength reduces tablet-splitting requirements and supports weight-based dosing.

The pediatric formulation may have greater commercial defensibility than the active ingredient. Its value comes from regulatory approval, dosing convenience, tolerability, and supply reliability. A competitor could nevertheless develop an equivalent low-strength tablet, compounded preparation, or alternative pediatric dosage form if regulatory and manufacturing requirements are satisfied.

Formulation protection is unlikely to support a high-margin franchise unless it is paired with exclusive distribution, a strong brand, or procurement advantages.

How does benznidazole compare with nifurtimox?

Benznidazole and nifurtimox are the two principal medicines used against Chagas disease. Both are older small molecules with finite treatment courses and substantial tolerability concerns.

Factor	Benznidazole	Nifurtimox
Drug class	Nitroimidazole	Nitrofurane
U.S. FDA approval	2017	2020
U.S. approved population	Pediatric patients ages 2 to 12	Pediatric patients from birth to under 18
Treatment role	Established first-line option	Alternative and first-line option depending on patient and setting
Patent profile	Historical compound protection expired	Historical compound protection expired or limited
Commercial model	Specialty and public-health supply	Specialty and public-health supply
Main differentiation	Pediatric 12.5 mg and 100 mg tablets	Broader U.S. pediatric age range
Competitive constraint	Limited diagnosed population	Limited diagnosed population and tolerability

Nifurtimox’s FDA approval broadened the U.S. treatment landscape and reduced dependence on benznidazole as the only FDA-approved pediatric option. Competition is based on age range, tolerability, physician preference, availability, and procurement contracts rather than on patent-protected clinical superiority.[3]

What is the commercial market for benznidazole?

The global Chagas disease burden is estimated at roughly 6 million to 7 million people, with most cases in Latin America. Only a minority of infected individuals are diagnosed and treated.[4] This creates a large epidemiological need but a smaller effective pharmaceutical market.

The market has four structural characteristics:

Public-health purchasing dominates

Many patients receive treatment through national health ministries, international organizations, hospitals, and nonprofit programs. Purchasing decisions are often based on price, supply reliability, and treatment guidelines.

The treatment course is finite

Benznidazole is generally administered for about two months. It does not create the recurring revenue profile of a chronic cardiovascular, diabetes, or autoimmune therapy.

Diagnosis limits demand

Many infected individuals remain undiagnosed for years. Screening expansion among migrants, pregnant women, blood donors, and people in endemic areas could increase treated volume, but diagnosis and follow-up capacity remain bottlenecks.

Geographic demand is concentrated

Argentina, Bolivia, Brazil, Mexico, and other Latin American markets account for much of the disease burden. The United States has a smaller diagnosed market, concentrated in states and metropolitan areas with large Latin American immigrant populations.

What is the financial trajectory for benznidazole?

Public companies and distributors do not generally disclose standalone benznidazole revenue in a manner that permits a reliable product-level financial model. The product is better classified as a niche specialty and public-health asset than as a material global revenue driver.

The likely financial trajectory has three stages:

Period	Financial characteristics
2017-2019	U.S. launch, regulatory uptake, physician education, limited pediatric demand
2020-2022	Pandemic-related diagnosis and treatment disruption, followed by normalization
2023 onward	Gradual volume growth tied to screening, public procurement, and geographic access

Revenue growth can occur through unit expansion without substantial pricing power. The main growth levers are:

• Greater diagnosis of congenital and chronic Chagas disease.
• Expansion of treatment into endemic Latin American populations.
• Increased screening in the U.S.
• Additional pediatric and adult formulations.
• Government tenders and international procurement.
• Reliable supply during shortages or manufacturing disruptions.

Price increases face constraints because Chagas disease is a neglected tropical disease and procurement customers are price-sensitive. A U.S. specialty price can generate higher revenue per course than Latin American public procurement, but the eligible U.S. population is much smaller.

What revenue exposure does benznidazole create?

For the product owner, revenue exposure is likely modest in absolute terms but strategically useful because the product occupies a regulatory-approved niche with limited branded competition. It can generate resilient specialty revenue if supply remains reliable and distribution rights are maintained.

For investors, benznidazole should not be valued like a conventional orphan blockbuster. Its value is more closely tied to:

• Contract duration.
• Annual treated-patient volume.
• Net price per treatment course.
• Government tender wins.
• Manufacturing cost.
• Regulatory expansion.
• Competitive entry.

Standalone revenue disclosure is insufficient to support a precise valuation without company-specific sales data.

Which companies are challenging benznidazole?

The competitive field includes established Latin American manufacturers, public-sector suppliers, nonprofit procurement channels, and potential generic applicants. Competition is fragmented rather than concentrated in a single global branded rival.

Relevant commercial entities have included:

• Exeltis USA in the United States.
• Laboratorios ELEA and related Latin American supply networks.
• Chemo Research and associated pharmaceutical development entities.
• Generic manufacturers in Brazil, Argentina, and other endemic markets.
• Government and nonprofit procurement organizations.

The main competitive threat is not a single patent challenger. It is the availability of lower-cost regional products, compounded preparations, government-supplied medicine, and alternative treatment with nifurtimox.

What generic entry risks exist for benznidazole?

Generic entry risk is high in principle because the compound is old and core patent protection has expired. Actual entry risk is moderated by the small market.

A generic launch could occur if an applicant can demonstrate:

• Pharmaceutical equivalence.
• Adequate manufacturing controls.
• Reliable active pharmaceutical ingredient supply.
• Pediatric dosage suitability.
• FDA approval or applicable local authorization.
• Sufficient commercial volume.

The most likely effect of generic entry would be price pressure in the U.S. and institutional channels. The impact on total treated patients could be positive if lower prices improve access.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are more important than intellectual-property barriers. Benznidazole production requires consistent control of active ingredient quality, impurities, tablet uniformity, stability, packaging, and pediatric dosing.

Supply interruptions could materially affect the market because the number of qualified manufacturers is limited relative to high-volume generic medicines. A company with validated manufacturing, regulatory approvals, and dependable API sourcing may retain commercial value even without strong patents.

Geographic coverage is also important. A supplier may have a strong U.S. position but limited access to Latin American tenders, or broad endemic-market coverage without FDA approval.

Key Takeaways

• Benznidazole is an established, off-patent treatment for Chagas disease.
• FDA approved the drug in 2017 for children ages 2 to 12.
• Original compound exclusivity and pediatric regulatory exclusivity have expired.
• The product has no meaningful molecule-level patent barrier to generic competition.
• Formulation, manufacturing, supply, and distribution rights matter more than core patents.
• No major public Paragraph IV litigation or settlement has materially delayed generic entry.
• Nifurtimox is the principal FDA-approved competitive alternative.
• Market growth depends on diagnosis, screening, public procurement, and geographic access.
• The treatment course is finite, limiting recurring revenue.
• Public disclosures do not support a reliable standalone revenue estimate.
• Benznidazole is a niche specialty and public-health asset, not a conventional blockbuster.

FAQs

Is benznidazole still patent protected in the United States?

The original benznidazole compound is not protected by a current composition-of-matter patent that would prevent generic development. Any relevant protection would more likely involve a specific formulation, manufacturing process, or method of use.

Does benznidazole have FDA orphan-drug exclusivity?

The product was approved for an orphan disease population and received regulatory benefits associated with its development. The applicable exclusivity period has expired and does not currently prevent competing approval.

Can adults receive benznidazole in the United States?

U.S. labeling has focused on pediatric patients ages 2 to 12. Physicians may consider treatment outside the labeled population where medically appropriate, but prescribing and reimbursement depend on clinical judgment, available evidence, and payer policy.

Is benznidazole more profitable than nifurtimox?

There is insufficient public product-level revenue data to establish a reliable profitability comparison. Benznidazole has an earlier U.S. market position, while nifurtimox has a broader labeled pediatric age range.

What would increase benznidazole sales most significantly?

Expanded Chagas screening, improved diagnosis of congenital infection, greater treatment coverage in Latin America, new adult indications, and broader access through government procurement would have the greatest potential to increase volume.

References

1. U.S. Food and Drug Administration. (2017). Benznidazole prescribing information and approval letter, NDA 209570. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2020). Lampit (nifurtimox) prescribing information and approval materials. https://www.accessdata.fda.gov
4. World Health Organization. (2023). Chagas disease (American trypanosomiasis). https://www.who.int/news-room/fact-sheets/detail/chagas-disease-american-trypanosomiasis